|
|
| Factor IX Human native protein |
 |
|
|
 |
| Catalog Number: 11-663-46072 |
|
|
|
| Related Product Names:
|
-
F9 native protein; F9; Factor IX Human
- Factor IX Human; EC 3.4.21.22; Christmas factor; Plasma thromboplastin component; PTC; factor IX |
|
- Gene Information -
Information in yellow represents specific gene information and does not necessarily represent specific product details. For more information please contact sales@genwaybio.com.
|
|
| Gene Name: F9 |
Gene Name Synonym: N/A |
Gi #:
N/A |
NCBI Acc #:
NP_000124.1 |
Swiss Prot Acc #:
P00740 |
Length (aa): N/A |
Mol. Weight (Da): 51778 |
Chrom Location: N/A |
|
|
 Biological Activity: HuFactor IX is fully biologically active when compared to standard.
The potency per mg was tested and found to be 167IU/mg.
Dimer Aggregates: Less than 1% as determined by silver stained SDS-PAGE gel analysis.
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
Solubility: It is recommended to reconstitute the lyophilized HuFactor-VIII in sterile 18M-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.
Source/Host: Hu Plasma
Purity/Purification: Greater than 98.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained.
Format: The lyophilized protein 400IU/ml was lyophilized from a sterile solution containing 10ppm TNBP, 100ppm Polysorbate 80, 500ppm PEG, 1.5% Glycine, 160mM Sodium chloride and 25mM Citrate.
Stability: Lyophilized HuFactor-IX although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. Upon reconstitution HuFactor-IX should be stored at 4 C between 2-7 days and for future use below -18 C.
Please prevent freeze-thaw cycles
Shipping: Products may be shipped on ice pack or dry ice. |
|
|
|
| F9 NATIVE PROTEIN TARGET DESCRIPTION: |
Synonym Names for F9 native protein: F9; Factor IX Human; EC 3.4.21.22; Christmas factor; Plasma thromboplastin component; PTC; factor IX
Human Factor IX is a glycoprotein, which is synthesized in the liver (1–3). The domain structure of factor IX is similar to that of the other vitamin K dependent coagulation factors. The NH2-terminal region contains 12 g-carboxyglutamic acid (gla) residues, which facilitate the calcium dependent binding of factor IX to negatively charged phospholipid surfaces. Two domains which are homologous to epidermal growth factor (EGF) span the region between the NH2-terminal gla domain and the activation peptide (Ala-146 to Arg-180). Factor IX is activated by either factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage at site A yields the intermediate IXa, which is subsequently converted to the fully active form IXab by cleavage at site B. The NH2-terminal light chain (GLA and EGF domains) remains covalently attached to the COOH-terminal heavy chain by a disulfide bond. The serine protease catalytic triad (Ser-365, His 221, Asp-269) is located in the heavy chain. Factor IXab is the catalytic component of the “intrinsic factor Xase complex” (factor VIIIa/IXa/Ca2+/phospholipid) which proteolytically activates factor X to factor Xa..
Function: Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca(2+) ions, phospholipids, and factor VIIIa.
Catalytic Activity: Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
Subunit: Heterodimer of a light chain and a heavy chain; disulfide-linked.
Subcellular Location: Secreted.
Tissue Specificity: Synthesized primarily in the liver and secreted in plasma.
Domain: Calcium binds to the gamma-carboxyglutamic acid (Gla) residues and, with stronger affinity, to another site, beyond the Gla domain.
Ptm: Activated by factor XIa, which excises the activation peptide.
Disease: Defects in F9 are the cause of recessive X-linked hemophilia B (HEMB) [MIM:306900]; also known as Christmas disease.
Disease: Mutations in position 43 (Oxford-3, San Dimas) and 46 (Cambridge) prevents cleavage of the propeptide, mutation in position 93 (Alabama) probably fails to bind to cell membranes, mutation in position 191 (Chapel-Hill) or in position 226 (Nagoya OR Hilo) prevent cleavage of the activation peptide.
Pharmaceutical: Available under the names BeneFix (Baxter and American Home Products). Used to treat hemophilia B.
Miscellaneous: In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Similarity: Belongs to the peptidase S1 family [view classification].
Similarity: Contains 2 EGF-like domains.
Similarity: Contains 1 Gla (gamma-carboxy-glutamate) domain.
Similarity: Contains 1 peptidase S1 domain [view classification].
OMIM: 306900; gene+phenotype. [NCBI / EBI]
Products similar to F9 native protein:
IgG
 ILF3 (interleukin enhancer binding factor 3. 90kDa), IgG
karyopherin (importin) beta 1 (KPNB1), IgG
SIT [SIT-01], IgG
CD137, IgG
KAP 1, IgG
Peptide
RFRP-1 Human, Peptide
FGF-9 Mouse, Protein
YEATS domain-containing protein 4, Protein
4-1BBR Human, Protein
|
|
|
SUGGESTED PROTEIN REAGENTS - GenWay offers reagents to facilitate your research with cell-based assays, Mass Spectrometry, standards, calibrators, Western blot, cell culture, antibiotics, microwell substrates, and more!
|
|
Order Confirmation: Sales order confirmations are sent out upon the receipt of all orders. Please contact GenWay if you do not receive a confirmation within 1 business day of submitting your order.
Precautions: F9 native protein is for in vitro research use only. Not for use in diagnostics or therapeutic procedures.
Important Notes: During shipment, small volumes of F9 native protein vial. For products with volumes of 200 µL or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container’s cap. Actual concentration, volume and quantity will be printed on the vial's label. Please refer to the vials label for this information.
Copyright: This GenWay TDS is copyrighted. This datasheet is produced based partially on data from Swiss-Prot/TrEMBL and NCBI. To better serve our clients with everything we know about F9 native protein, all related information, articles, resources about F9 native protein are being stored on our online database. Let us know if you have questions regarding this product.
Disclaimer: For documents and software available from this server, GenWay neither warrants nor assumes any legal liability or responsibility for the accuracy, completeness or utility of any information, product or process disclosed. |
|
|
|
GenWay is a Protein and Antibody Solutions Provider. Customer Satisfaction is Our Top Priority.
|
GenWay has a diverse line of recombinant protein expression platforms, including E. coli expression, Bacliovirus expression, yeast expression, and mammalian expression. Combining the technologies of bioinformatics, protein domain analysis, gene codon optimization, protein fusion, and protein expression in different host cells, GenWay can produce soluble and functional proteins. In particular, GenWay has the capability and vector systems for expression of difficult proteins such as proteases, kinases, glycosylated and membrane proteins. We have a very high success rate (almost 100%) and can deliver the proteins in a timely fashion. This is a core competency necessary for efficient and effective production of immunogens and affinity ligands for antibody production and purification. GenWay has over 300 recombinant proteins offered in our catalog. |
|
|
|
